Clinical Trials | May 14, 2026
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Subscribe To Our Newsletter & Stay Updated
